Metsera initiated with a Buy at Guggenheim

Guggenheim initiated coverage of Metsera (MTSR) with a Buy rating and $56 price target The firm sees a “highly promising multi-billion opportunity” for the company’s ultra-long-acting nutrient stimulating hormone analog pipeline. Metsera is positioned to take a stake in the growing obesity market, the analyst tells investors in a research note. Guggenheim has confidence Metsera can get its programs to the finish line, and recommends investors build a position well before 097i monthly dosing and initial 097i/233i combination data hit in late 2025.